Alcohol and Alcoholism Vol. 35, No. 2, pp. 176-187, 2000
© 2000 Medical Council on Alcoholism
UNITED KINGDOM MULTICENTRE ACAMPROSATE STUDY (UKMAS): A 6-MONTH PROSPECTIVE STUDY OF ACAMPROSATE VERSUS PLACEBO IN PREVENTING RELAPSE AFTER WITHDRAWAL FROM ALCOHOL
University of Edinburgh, Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh EH10 5HF,
1 Lipha (UK), Harrier House, West Drayton, Middlesex and
2 University Department of Medicine, Royal Free Campus, Royal Free and University College Medical School, London NW3 2QG, UK
Received 13 May 1999; first review notified 1 August 1999; accepted 20 August 1999
A 6-month randomized controlled study of acamprosate versus placebo in preventing relapse following withdrawal from alcohol was undertaken in 20 centres throughout the UK. Patients diagnosed as alcohol-dependent and detoxified within the preceding 5 weeks were randomly assigned to treatment with either acamprosate (A) 666 mg three times/day or identical placebo (P). A total of 664 patients were screened; 581 were entered into the treatment phase. One-third were episodic drinkers, 84% were male, 44% were unmarried and 48% were unemployed. Medication was first taken on average 24 days after the start of detoxification; 32% of patients had already relapsed by this time. The 6-month study period was completed by 35% of patients; adverse events led to withdrawal of a further 14% (A) and 9% (P) respectively. Compliance was poor in that, by the end of the second week, only 57% of patients were judged to be taking at least 90% of their tablets. The mean total of abstinent days achieved was 77 (A) and 81 (P). Complete abstinence for 6 months was achieved by 12% (A) and 11% (P); drinking remained within controlled limits in a further 3% (A) and 6% (P). An effect of acamprosate on consumption was not seen when subgroups, including those defined by the Lesch typology, were analysed separately. However, the mean percentage reduction in craving for alcohol measured on a visual analogue scale was greater in the acamprosate, than placebo, patients at week 2 and week 4 (P < 0.001) and the mean decrease in the Hamilton Anxiety score at the 4th week was greater in the acamprosate than placebo patients (P = 0.017). In comparison with other published trials of acamprosate, patients started study medication after a longer time following detoxification, had more often recommenced drinking before medication was started and had a higher drop-out rate, and this might have contributed to the lack of a treatment effect in this study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Newham, C. Russell, and J. B. Davies Planned and Unplanned Discharge from Alcohol Services in Scotland, 2004-2008 Alcohol Alcohol., November 12, 2009; (2009) agp081v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rao and J. Luty The future of specialised alcohol treatment services: a matter of policy? Adv. Psychiatr. Treat., July 1, 2009; 15(4): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Olmsted and D. R Kockler Topiramate for Alcohol Dependence Ann. Pharmacother., October 1, 2008; 42(10): 1475 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Luty and T. Carnwath Specialised alcohol treatment services are a luxury the NHS cannot afford The British Journal of Psychiatry, April 1, 2008; 192(4): 245 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hillemacher and S. Bleich Neurobiology and Treatment in Alcoholism--Recent Findings Regarding Lesch's Typology of Alcohol Dependence Alcohol Alcohol., March 13, 2008; (2008) agn016v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Peterson Improving adherence in patients with alcohol dependence: A new role for pharmacists Am. J. Health Syst. Pharm., March 1, 2007; 64(5_Supplement_3): S23 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Mason Acamprosate for Alcohol Dependence: An Update for the Clinician Focus, September 1, 2006; 4(4): 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. N. CARDOSO, A. BARBOSA, F. ISMAIL, and S. POMBO NETER ALCOHOLIC TYPOLOGY (NAT) Alcohol Alcohol., March 1, 2006; 41(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McPherson and C. J. Rees An alcoholic patient who continues to drink: case outcome BMJ, February 4, 2006; 332(7536): 276 - 276. [Full Text] [PDF]
|
|
|
|
|
|
J. Luty What works in alcohol use disorders? Adv. Psychiatr. Treat., January 1, 2006; 12(1): 13 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]
|
|
|
|
|
|
J. Chick, P. Lehert, and F. Landron Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence? J Psychopharmacol, December 1, 2003; 17(4): 397 - 402. [Abstract] [PDF]
|
|
|
|
 |
|
 Susan. F. Tapert, E. H. Cheung, G. G. Brown, L. R. Frank, M. P. Paulus, A. D. Schweinsburg, M. J. Meloy, and S. A. Brown Neural Response to Alcohol Stimuli in Adolescents With Alcohol Use Disorder Arch Gen Psychiatry, July 1, 2003; 60(7): 727 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P Overman, C. J Teter, and S. K Guthrie Acamprosate for the Adjunctive Treatment of Alcohol Dependence Ann. Pharmacother., July 1, 2003; 37(7): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Namkoong, B.-O. Lee, P.-G. Lee, M.-J. Choi, and E. Lee ACAMPROSATE IN KOREAN ALCOHOL-DEPENDENT PATIENTS: A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY Alcohol Alcohol., March 1, 2003; 38(2): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Willinger, E. Lenzinger, K. Hornik, G. Fischer, G. Schonbeck, H. N. Aschauer, and K. Meszaros ANXIETY AS A PREDICTOR OF RELAPSE IN DETOXIFIED ALCOHOL-DEPENDENT PATIENTS Alcohol Alcohol., November 1, 2002; 37(6): 609 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rubio, M. A. Jimenez-Arriero, G. Ponce, and T. Palomo NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT Alcohol Alcohol., September 1, 2001; 36(5): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Kranzler PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH Alcohol Alcohol., November 1, 2000; 35(6): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chick, R. Anton, K. Checinski, R. Croop, D. C. Drummond, R. Farmer, D. Labriola, J. Marshall, J. Moncrieff, M. Y. Morgan, et al. A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE Alcohol Alcohol., November 1, 2000; 35(6): 587 - 593. [Abstract] [Full Text] [PDF]
|
|